UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy

Leandro, MJ; Cooper, N; Cambridge, G; Ehrenstein, MR; Edwards, JCW; (2007) Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. RHEUMATOLOGY , 46 (1) 29 - 36. 10.1093/rheumatology/kel148.

Full text not available from this repository.

Abstract

Objective. To assess the presence and phenotype of B-lineage cells in the bone marrow (BM) of rheumatoid arthritis (RA) patients after rituximab therapy.Methods. Six patients were studied. BM aspirates were collected 3 months after the treatment and analysed using the four-colour flow cytometry.Results. CD19+ (B-lineage) cells in BM samples varied from 0.1 to 3.25% in the lymphoid gate. CD34+ cells varied from 1.23 to 4.86%. The proportion of CD34+ cells committed to the B-lineage varied between 0 and 42.19%. Pro-B-cells were undetectable in one case. The majority of B-cell precursors were pro-B-cells in Patients 5 and 6 (50 and 62% of CD19+ cells, respectively), pre-B-cells in Patients 3 and 4 (64 and 70%) and immature B-cells in Patient 1 (44%). Detectable CD20 expression on CD19+ cells was either low or absent. Plasma cells varied from 0.01 to 0.36% of the total nucleated cells. There was a trend towards longer duration of clinical response in patients with evidence of more complete depletion in BM.Conclusion. In this small cohort of RA patients treated with rituximab, differences in proportion and phenotype of CD19+ BM cells were detected. These differences suggest variation in the degree of depletion achieved and correlate with time to relapse. Although pro-B-cells are not targeted directly by rituximab as they do not express CD20, the levels were unexpectedly low.

Type: Article
Title: Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
DOI: 10.1093/rheumatology/kel148
Keywords: rheumatoid arthritis, rituximab, B-cell depletion, bone marrow, SYSTEMIC-LUPUS-ERYTHEMATOSUS, ACUTE LYMPHOBLASTIC-LEUKEMIA, MONOCLONAL-ANTIBODY THERAPY, MINIMAL RESIDUAL DISEASE, FLOW-CYTOMETRIC ANALYSIS, NON-HODGKINS-LYMPHOMA, PLASMA-CELLS, LOW-GRADE, DEPLETION, CD20
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: http://discovery.ucl.ac.uk/id/eprint/146648
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item